Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The data showed that PCFL was significantly increased in hearts of mice subjected to MI and CFs treated with transforming growth factor-β1 (TGF-β1).
|
31220469 |
2019 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, TGF-β1 may impede the full benefit of corrector/potentiator therapy in CF patients.
|
31590401 |
2019 |
Cystic Fibrosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Pulmonary TGFβ1 expression was sufficient to produce pulmonary remodeling and abnormalities in lung mechanics that were associated with both shared and unique cell signaling pathway activation in CF and non-CF mice.
|
29877096 |
2018 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The present results demonstrated that osthole could inhibit the collagen I and III expressions and their ratio in CFs treated with TGF-β1 via Smad signaling pathway, which might be one of its anti-fibrotic action mechanisms.
|
27870967 |
2017 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Additionally, it was demonstrated that cell population of CFs treated with NRG in the S-phase became smaller whereas that of CFs in the G0/G1-phase increased when compared with the TGF-β1 group.
|
29104653 |
2017 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, we propose that TGF-β1-induced mucociliary dysfunction in CF airways is associated with BK inactivation related to a LRRC26 decrease and is amenable to treatment with clinically useful TGF-β1 inhibitors.
|
26338706 |
2015 |
Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
On the basis of our results, the -509C/T polymorphism of the TGFB1 gene seems to be a modulator factor of cystic fibrosis.
|
26277914 |
2015 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The cytokine TGF-β1 is frequently elevated in CF patients.
|
23671668 |
2013 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
TGF β 1 in IS (CF/controls median 76.5/59.1 pg/mL, P < 0.074) was higher in CF.
|
24062613 |
2013 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
On 19q13, TGFB1 and the cystic fibrosis modifier 1 locus (CFM1) have been identified as modifiers of the course of the monogenic disease cystic fibrosis (CF).
|
20047061 |
2010 |
Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis.
|
19466271 |
2009 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
To assess whether any of 9 polymorphisms in 5 candidate genes (alpha(1)-antitrypsin or alpha(1)-antiprotease [SERPINA1], angiotensin-converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor beta1 [TGFB1]) are associated with severe liver disease in patients with CF.
|
19738092 |
2009 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that TGFB1 is a modifier of CF lung disease and reveal a previously unrecognized beneficial effect of TGFB1 variants upon the pulmonary phenotype.
|
18424453 |
2008 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this issue of the JCI, Dorfman et al. demonstrate in a large, population-based study that two previously studied modifier genes, coding for mannose-binding lectin 2 and TGF-beta1, influence pulmonary outcome in pediatric CF patients (see the related article beginning on page 1040).
|
18292812 |
2008 |
Cystic Fibrosis
|
0.700 |
GermlineModifyingMutation
|
disease |
ORPHANET |
These results demonstrate that TGFB1 is a modifier of CF lung disease and reveal a previously unrecognized beneficial effect of TGFB1 variants upon the pulmonary phenotype.
|
18424453 |
2008 |
Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings support the concept that TGFB1 gene variants appear to be important genetic modifiers of lung disease progression in CF.
|
19009622 |
2008 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, the role of TGFbeta1 as a CF modulator, suggested from studies with a case-control setting, needs to be interpreted with caution unless family-based analysis is carried out to identify parental genetic and non-genetic effects.
|
17406643 |
2007 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
LHGDN |
In CF, both extremes, highest or lowest TGF-beta 1 production, were associated with impaired lung function.
|
17052957 |
2006 |
Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We did not prove the association of TGF-beta1 polymorphisms and lung function in CF, however, the TT (codon 10)/GG (codon 25) genotype was preferentially associated with CF-related liver disease and diabetes.
|
17052957 |
2006 |
Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Genetic modifiers of lung disease in cystic fibrosis.
|
16207846 |
2005 |
Cystic Fibrosis
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease.
|
12000722 |
2002 |
Cystic Fibrosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We conclude that a CF-related reduction in Smad3 protein expression selectively alters TGF- beta1-mediated signaling in CF epithelium, potentially contributing to aggressive inflammatory responses.
|
11726399 |
2001 |
Cystic Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TGF-beta(1) genotypes may have a role in mediating pulmonary dysfunction in patients with cystic fibrosis.
|
10817792 |
2000 |
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Cystic Fibrosis
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|